141 Oligonucleotides Companies - Worldwide
Search through all Oligonucleotides companies with powerful filtering options
Company Name | Location | About |
---|---|---|
ACADIA Pharmaceuticals | San Diego, California, United States of America | ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. |
Accurant Biotech | Cranbury, New Jersey, US | |
ADARx Pharmaceuticals | San Diego, California, United States of America | ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease. |
AiCuris | Wuppertal, Germany | AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused on the discovery, research and development of novel antiviral agents for the treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients. Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris has a broad and innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its focus on specialist markets with high medical need, the company is perfectly positioned for growth and success. |
AIRNA | Cambridge, Massachusetts, United States | AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+. |
Ajinomoto | Itasca, Illinois, United States | Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products. |
Amoy Diagnostics | Xiamen, China | Amoy Diagnostics (AmoyDx) is a visionary diagnostic company dedicated to transforming the landscape of cancer care. 'Breaking Barriers to Precision Oncology' reflects our commitment to revolutionizing cancer diagnosis and treatment. We are driven by four fundamental values: Innovation in Care, Accessibility and Equity, Collaboration and Partnership, and Integrity and Trust. These values guide our pursuit of developing groundbreaking diagnostic tools and fostering a more equitable, collaborative, and trustworthy approach to oncology. Join us as we pave the way to a future where precision cancer care is a reality for every patient, everywhere. |
AnGes Inc. | Tokyo, Japan | AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. Both our founder and our employees are still motivated by this desire. |
Antisense Therapeutics | Melbourne, Victoria, Australia | Previously Antisense Percheron Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. |
Aptadir Therapeutics | Milan, Italy | Reprogramming DNA methylation in disease conditions by RNA therapeutics APTADIR Contact us NEWS Press Release Reprogramming DNA methylation by RNA therapeutics A novel therapeutic approach for untreatable cancers and rare diseases Aberrant methylation by DNA methyltransferase 1 (DNMT1) of certain genes may cause abnormal cell development and lead to disease. Current therapies targeted to inhibit |
Aptamer Sciences | Gyoungbuk, South Korea | Aptamer Sciences Inc. is a privately held biotech company focused on commercializing cutting-edge technologies for analysis of proteins, based on its proprietary aptamer technology platforms. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics. Compared to conventional aptamer generating technologies, Aptamer Sciences has developed advanced aptamer technologies and thus can generate aptamers more efficiently with superior binding affinity. Aptamer Sciences has ongoing collaboration relationships with several industry partners. The Company also has research collaboration with several universities, hospitals and research organizations. Aptamer Sciences was founded in 2011 by researchers from POSTECH BIOTECH CENTER and is based in Pohang, South Korea. Aptamer Sciences is currently funded by aptamer service revenue and grants, as well as by investments from strategic investors. |
AptamiR Therapeutics | Austin, Texas, United States | AptamiR Therapeutics has created an innovative model of virtual and outsourced Drug Research & Development to cure human obesity by developing microRNA-based treatments that target peripheral adipose tissues (fat cells). |
ArcherDx | 2477 55th Street, Suite 202, Boulder, Colorado 80301, US | ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies. |
Arnatar Therapeutics | 10355 Science Center Drive, Suite 130 | Harnessing the power of RNA biology to find treatments for patients with unmet medical needs. Advance and utilize the cutting edge antisense technology (siRNA and ASO) to discover and develop next generation medicines for both large and rare disease indications. |
Aro Biotherapeutics | Philadelphia, Pennsylvania, United States | Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. |
Aronora | Portland, Oregon, United States | Aronora is a translational biotechnology company (aronorabio.com) engaged in the development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases. |
Aros Applied Biotechnology | Aarhus, Denmark | Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 61 countries and 61,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. Our services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Imprint: https://www.eurofinsgenomics.eu/imprint/ Privacy Note: https://www.eurofinsgenomics.eu/privacy/ |
ARTHEx Biotech | Paterna, Valencia, Spain | ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com |
Aum LifeTech | Philadelphia, Pennsylvania, United States | AUM LifeTech is an American Biotechnology company focused on using next-generation RNA silencing technology to develop solutions in diverse life science verticals including biomedical research, medicine, agriculture, and aquaculture. Specifically, AUM's custom products include next generation of innovative genetic tools in the area of gene silencing and manipulation for biomedical research and therapeutic development. AUM’s non-GMO products are also being developed for broad-spectrum target-specific pest management and disease control in agriculture. RNA silencing products using FANA technology provide superior alternatives to conventional RNAi and gene editing approaches like CRISPR and provide a fast track target discovery. AUM's goal is to provide innovation at the genetic level for a better life. |
AusperBio | Hangzhou, China | AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio's strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs. |
Avidity Biosciences | San Diego, California, United States | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. |
Axcelead Drug Discovery Partners | Fujisawa, Japan | Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery. |
Axolabs | Kulmbach, Germany | Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world's leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis. |
Bachem | Bubendorf, Switzerland | Peptides, APIs |
Baseclick | Munich, Germany | At baseclick GmbH we believe that bioconjugation is not just a method to connect (bio)molecules, but a tool to develop valuable applications. So, a new strategy was needed: click chemistry! " Nobel Prize 2022, the basis of the baseclick patented nucleic acid modification technology". We are a dynamic, highly professional team and enabling life science researchers to overcome challenges and create better solutions in diagnostics, therapeutics, and vaccines development through our proprietary click chemistry. Our mission is to develop and provide the best nucleic acid labeling applications and reagents for the life science market. For further information please visit our website https://www.baseclick.eu/ https://www.baseclick.eu/our-vaccine-strategy-and-its-benefits/ |
Biogen | Cambridge, Massachusetts, United States of America | Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. |
Biomarin Pharmaceutical Inc. | Novato, California, United States of America | BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. |
Bioneer | Oakland, California, United States | Since its founding in 1992 Bioneer Corporation has established market leadership in Korea for most of the products it manufactures. Bioneer has built its business by providing researchers with superior, high quality products at excellent value. Over the years, Bioneer has developed a broad range of unique products that provide total genomic research solutions for life sciences research including genomics, nucleic acid-based molecular diagnostics and gene therapy studies. Bioneer has extensive R&D experience in developing new drugs as well as the use of siRNA and drug delivery systems, and provides unrivalled service and support for such tools. For example, through the creation, development, and commercialization of the S. pombe deletion mutant library, Bioneer provides an innovative tool for improving the development of new drugs. The S. pombe library accurately predicts the toxicity of drug candidates for anti-cancer, Hyperlipidemia and also provides molecular level mechanism analysis of natural compound drugs. The company is headquartered in South Korea with an oligonucleotide manufacturing facility in the U.S., a regional office in China, and is supported by a network of distributors throughout the world. For more information, please visit www.bioneer.com. |
BioPAL_ | Worcester, Massachusetts, United States | MRI contrast reagents |
BIORON | Römerberg, Germany | BIORON GmbH is a producer and worldwide acting trader of molecular biological and diagnostic products. Our main focus are ready-to-use solutions for professionals, i.e. high concentrated polymerases for lyophilisation. |
BioSpring GMBH | Frankfurt, Germany | |
BOC Sciences | Shirley, New York, United States | BOC Sciences provides a wide variety of custom services which range from bulk compounds to specialty species in the pharmaceutical, agrochemical, and biotechnology industries. We are committed to providing our customers with the best products and services at the most competitive prices. Given diverse packing options for most of our chemicals, you are welcome to order the desired compounds in any quantities from a few mg to several kg along with all the relevant technical reports. We sincerely hope that our unremitting pursuits of excellence, success, and professionalism will add immense value to your research and development projects! |
Bolden Therapeutics | Providence, Rhode Island, United States | Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway. |
Bound Therapeutics | Marlton, New Jersey, United States | Bound Therapeutics LLC creates next generation healthcare solutions by developing RNA-based drugs for various diseases, immersive haptic surgical simulation, and artificial intelligence automated medical imaging analysis. |
Capricor Therapeutics | Beverly Hills, California, United States of America | Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California. |
Cardior Pharmaceuticals | Hanover, Germany | Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. |
ChemGenes | Wilmington, Massachusetts, United States | At ChemGenes, we redefine the limits of scientific discovery, development and commercialization by manufacturing the broadest range of modified chemistries available in today's market. We produce building blocks of life used by scientists and physicians in academic institutions, as well as pharmaceutical and biotechnology companies around the globe, to accelerate breakthroughs, spark innovation and develop lifesaving diagnostics and medicines. Established in 1981, ChemGenes is the world's most experienced DNA and RNA manufacturing company. As a trailblazer in nucleic acid research and synthesis for nearly half a century, ChemGenes has earned its position as a market leader in the field of nucleic acid chemistry. With our state-of-the-art manufacturing facility located just North of Boston, ChemGenes is customer centric, nimble and well positioned to scale alongside our partners. We've helped manufacturers introduce vital new medicines and – in an achievement with truly global implications – manufactured critical materials used in lifesaving COVID-19 vaccines and diagnostics. But beyond even these accomplishments, what sets us apart is our compassionate approach toward our customers, vendors and employees. We are a potent force for good, a close-knit and supportive team whose commitment to science, innovation and discovery is matched by – perhaps even exceeded by – our passion for helping people and changing lives for the better. |
CiVi Biopharma | Chevy Chase, Maryland, United States | CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases. |
Codexis Inc. | Redwood City, California, United States of America | Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. |
Corden Pharma | Chenôve, France | CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com |
CordenPharma | Plankstadt, Germany | CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com |
Couragene | 675 US Highway 1 | Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders. |
CPC Scientific | Sunnyvale, California, United States | Founded in 2001, we are the third largest peptide-focused contract research, development, and manufacturing organization (“CRDMO”) worldwide in terms of sales revenue in 2023, according to Frost & Sullivan. We are also considered one of the most comprehensive peptide-focused CRDMO globally (Frost & Sullivan), offering complete life-cycle support from early-discovery, pre-clinical research and clinical development to commercial production. We mainly provide (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers wit peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide. In addition to peptides, we have developed a diverse project pipeline focusing on various types of complex peptide- and oligonucleotide-based new chemical entities (“NCEs”). Our peptide conjugation services seamlessly integrate our peptide and oligonucleotide platforms to produce a wide range peptide conjugates products. The introduction of our PeptiConjuXTM and PeptiNuclide LinkTechTM are dedicated to the development and large-scale manufacturing (i.e., kilogram-scale) of peptide-oligonucleotide conjugates (“POC”), peptide drug conjugates (“PDC”), and radionuclide drug conjugates (“RDC”). As of December 31, 2023, we had successfully synthesized approximately 1,800 molecules through these two platforms. |
Creyon Bio | San Diego, California, United States | Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible. |
CustomArray | Bothell, Washington, United States | CustomArray, Inc. is a company dedicated to providing products and services to the "Omics" marketplace. CustomArray can provide instruments such as the B3™ Synthesizer that uses semiconductor arrays to rapidly synthesize DNA arrays "on chip". Arrays can be synthesized automatically on the instrument using either the 4x2k™, 12k™, or 90k™ array chips. In situ synthesis on up to 32 arrays (for 4x2k format) or 8 arrays (for other formats) can be performed in under 24 hours. We can also provide pre-made arrays ready for your experiment, and arrays can be read either using standard fluorescence chip readers (one-color or two-color readouts) or can be read using electrochemical detection on our ElectraSense reader. CustomArray also offers extensive services using our platforms to measure gene expression, to measure microRNA expression, to identify aptamer sequences (DNA sequences that bind with high affinity to customer-provided proteins), to identify potent siRNA sequences against select targets in vitro and validate the function of these targets both in vitro and in vivo, to provide large pools of oligos for specific applications such as sequencing, as well as other services. More information on products and services is in the "products" section of the website. We look forward to continuing to supply essential products to previous customers and welcome new customers to explore the advantages of our technologies and services. |
Cystic Fibrosis Foundation | Bethesda, Maryland, US | The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for people with cystic fibrosis, a rare, genetic disease in which a defective gene causes a thick buildup of mucus in the lungs, pancreas, and other organs. The buildup of mucus can lead to extensive lung damage, respiratory failure, malnutrition, liver disease, and gastrointestinal issues, among many other complications. Recognized globally, the Cystic Fibrosis Foundation has led the way in the fight against cystic fibrosis, fueling extraordinary medical and scientific progress. Working alongside the CF community, the CF Foundation has fostered the development of more than a dozen CF treatments — an unprecedented number in a short span of time — and helped add decades of life for people with CF. Thanks to this work, the life expectancy of someone born with CF has doubled in the last 30 years. We are driven by a dream that one day every person with cystic fibrosis will have the chance to live a long, healthy life. Our vision is a cure for every person with cystic fibrosis and a life free from the burden of this disease. While our headquarters are in Bethesda, Maryland, we have additional offices in more than 60 locations across the country with positions in fundraising, marketing, digital, information technology, legal, finance and more – all supporting our mission to cure cystic fibrosis. At the Foundation, we are committed to creating an environment that is free from discrimination and provides a rewarding experience for all members of our team. We strive to be an organization where everyone is welcomed and where talented individuals from all backgrounds have the opportunity to thrive. The CF Foundation is a nonprofit, donor-supported organization and an accredited charity of the Better Business Bureau's Wise Giving Alliance. Please visit us at www.cff.org. |
Deep Genomics | Toronto, Canada | Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology. |
DNA Software | Ann Arbor, Michigan, United States | DNA Software is the preferred partner to solve your diagnostic design and analysis problems.Our customized software platform predicts the “sweet spots” in the target and designs with optimum sensitivity and specificity. DNA Software provides diagnostic solutions to our partners saving time, money and resources, including difficult multiplex panel design for the most challenging targets. |
DNA Technology (Biosearch Technologies) | Risskov, Denmark | Whether you’re developing molecular diagnostic tests, clinical genomics assays, novel oligo therapeutics or using genotyping to develop improved, sustainable crops - high-quality, accurate data is critical to your success. LGC Biosearch Technologies provides mission-critical analysis tools, reagents and instruments to companies that are bringing new products to market quickly, cost-effectively, and safely. Our combined expansive portfolio and cross industry in-depth expertise enables us to provide you with comprehensive, competitive and innovative support across your entire genomics workflow and at every stage of your product development pipeline. From R&D through to large- scale commercialisation, our products and services scale up when you do. |
Duet BioTherapeutics | Los Angeles, California, United States | Duet BioTherapeutics is an immunotherapy company creating a new category of bispecific oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. Activation of these antigen-presenting cells removes the immunosuppressive shield around the tumor and jump-starts T cell-mediated immune responses to kill cancer cells. |